Levonordefrin

Cat. No.:	HY-107915				
CAS No.:	829-74-3				
Molecular Formula:	C ₉ H ₁₃ NO ₃				
Molecular Weight:	183.2				
Target:	Adrenergic Receptor				
Pathway:	GPCR/G Protein; Neuronal Signaling				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (272.93 mM; Need ultrasonic) H ₂ O : 5 mg/mL (27.29 mM; ultrasonic and warming and adjust pH to 1 with HCl and heat to 60°C)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	5.4585 mL	27.2926 mL	54.5852 mL	
		5 mM	1.0917 mL	5.4585 mL	10.9170 mL	
		10 mM	0.5459 mL	2.7293 mL	5.4585 mL	
	Please refer to the solu	ubility information to select the ap	propriate solvent.			
In Vivo	 Add each solvent o Solubility: 2.5 mg/r Add each solvent o Solubility: 2.5 mg/r 	ne by one: 10% DMSO >> 40% PE mL (13.65 mM); Suspended solution one by one: 10% DMSO >> 90% (20 mL (12.65 mM); Suspended solution	G300 >> 5% Tween-80 n; Need ultrasonic % SBE-β-CD in saline)) >> 45% saline		
	Solubility: 2.5 mg/r	The (13.65 mm), suspended solution	i, Neeu uttrasoffic			

Description	Levonordefrin, a common alternative to levoepinephrine as a vasoconstrictor in dental local anesthetic prepara
	usually used in fivefold higher concentrations. Levonordefrin is generally considered equivalent to epinephrine

REFERENCES

[1]. Robertson VJ, et al. Quantitative and qualitative analysis of the pressor effects of levonordefrin.

 $\underset{\mathbb{I}}{\mathbb{N}}H_2$

ŌΗ

OH

ΟH



Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA